drugset / Trial / NCT01949233

The Oxford Marfan Trial

NCT01949233

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the trial is to estimate the effects of allocation to irbesartan, or doxycycline, or a combination of both irbesartan and doxycycline, compared with placebo, on measures of elastic function of the aorta in people with the Marfan syndrome and enlargement of the aorta.

Timeline

Start
2013-10
Primary completion
2015-10
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 100 mg
Subject Doxycycline Small molecule 200 mg
Subject Irbesartan Small molecule 150 mg
Subject Irbesartan Small molecule 300 mg

Indications